Adaptimmune Therapeutics plc Cash Flow Reinvestment Rate

Latest as of June 2024: 0.03x

Adaptimmune Therapeutics plc cash flow reinvestment rate. Adaptimmune Therapeutics plc (473A) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting €1.50 Million (capex €754.00K plus investments €-743.00K) from operating cash flow of €47.40 Million. Explore debt repayment capacity of Adaptimmune Therapeutics plc to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.03x

(Capex + Investments) / Operating CF

Total Reinvested

€1.50 Million

Capex + Investments

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Cash Flow Reinvestment Rate of Adaptimmune Therapeutics plc (2021–2021)

Cash flow reinvestment rate of Adaptimmune Therapeutics plc from 2021 to 2021. Historical reinvestment intensity for Adaptimmune Therapeutics plc across 1 annual periods. Explore Adaptimmune Therapeutics plc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Adaptimmune Therapeutics plc Cash Flow Reinvestment Rate by Year (2021–2021)

Adaptimmune Therapeutics plc cash flow reinvestment rate by year from 2021 to 2021. Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics plc. For the full cash flow conversion analysis, see 473A operating cash flow.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	8.68x	€93.16 Million	€10.73 Million	€8.57 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow